Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

• Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s innovative Adult Adipose Allogeneic (AAA) stem cell programs

• Strengthened team with appointment of Dr. George E. Peoples, MD, FACS, Associate Professor of Surgical Oncology at MD Anderson Cancer Center, to the company’s Board of Directors,
  and the addition of Mark Gilbert, MD, scientist emeritus at the National Institutes of Health (NIH), to the Medical Advisory Board

• Received a new U.S. patent for the company’s novel SuperNova technology, which will allow Calidi to advance its CLD-201 program into the clinic. The patent covers a unique cancer treatment that combines stem cells and a smallpox vaccine, strengthening Calidi’s position in the development of innovative therapies for advanced solid tumors.

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSEAM: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted anti-tumor virotherapies, today reported operational and financial results for the second quarter ended June 30, 2024 and discussed recent business highlights.

“Calidi is making solid progress in our development programs and continues to innovate and expand our industry leadership in targeted anti-tumor virotherapies,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. “In addition, we are proud to have received a new U.S. patent for our SuperNova technology, further strengthening our IP position as we advance the CLD-201 program into the clinic.”